Telix Pharmaceuticals Limited · ASX:TLX
Telix Pharmaceuticals — Shareholder Meeting (May 2026)
46 slides from Telix Pharmaceuticals's shareholder meeting presentation, May 21, 2026
Slide 1: Annual General Meeting of Shareholders
For personal use only Annual General Meeting of Pre- treatment Shareholders Telix Pharmaceuticals ASX: TLX | NASDAQ: TLX May 21, 2026 18F-FET scan published in EJNMMI showing a patient with recurrent glioblastoma (GBM) who experienced a near-complete response following treatment with TLX101-Tx (Iodo
Slide 2: Forward looking statement
Forward looking statement This presentation should be read together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on
Slide 3: Kyahn Williamson, SVP Investor Relations
Kyahn Williamson For personal use only SVP Investor Relations and Corporate Communications
Slide 4: Voting and questions
Voting and questions • A poll will be conducted on all resolutions For personal use only • Vote at any time during the meeting • Virtual Meeting Online Guide provides detailed steps on how to vote and ask questions online – audio and written • Chairman intends to vote all undirected votes in favor o
Slide 5: Mark Nelson, Interim Chairman
Mark Nelson For personal use only Interim Chairman
Slide 6: Board of Directors
Board of Directors For personal use only Mark Nelson Christian Jann Skinner Marie McDonald David Gill William Jellison Maria Rivas, MD Behrenbruch Interim Chair and Non-Executive Non-Executive Non-Executive Non-Executive Non-Executive Non-Executive Managing Director Director Director Director Direct
Slide 7: Meeting agenda
Meeting agenda For personal use only 01 Chairman’s address 02 CEO’s address 03 Formal items of business, including voting and questions
Slide 8: Chairman's address
Illustration of TLX591-Tx Lutetium (177Lu) rosopatamab tetraxetan Annual General For personal use only Meeting of Shareholders Chairman’s address Mark Nelson
Slide 9: Our purpose
For personal use only Our purpose is to help people with cancer and rare diseases live longer, better quality lives.
Slide 10: CEO's address
Annual General For personal use only Meeting of Shareholders CEO’s address Dr. Christian Behrenbruch TLX250-CDx PET positive scan showing CAIX expression (Phase III ZIRCON study)
Slide 11: Five pillars underpinning our global leadership in radiopharma
Five pillars underpinning our global leadership in radiopharma For personal use only Integrated Theranostic Approach See It. Treat It. High value R&D platform for Precision Specialist Vertically therapeutics new molecular Medicine commercial integrated pipeline entities portfolio organization manufa
Slide 12: 2026 Strategic priorities
2026 Strategic priorities Strategic prioritization of capital and resources to deliver on near-term milestones Continue commercial Launch new Advance five high-value clinical For personal use only 1 growth 2 products 3 programs • Strong Q1 result, revenue up • Pixclara®2 (U.S.) resubmission • TLX591
Slide 13: Strategic collaboration with Regeneron
Strategic collaboration with Regeneron (NASDAQ: REGN) Highly complementary capabilities present a unique opportunity For personal use only • Collaboration to jointly develop and commercialize next generation radiopharmaceutical therapies, including targeted alpha therapies1 • Telix received US$40 mi
Slide 14: The Telix advantage: Integrated value ecosystem
The Telix advantage: Integrated value ecosystem Combining clinical excellence, service & innovation to drive market leadership For personal use only Expanding portfolio – Product multi-product platform and Innovation lifecycle management Customer centric & Commercial systematic approach Experience →
Slide 15: Diagnostic accuracy of 68Ga-PSMA-11
Diagnostic accuracy of 68Ga-PSMA-11 Illuccix and Gozellix supported by extensive published data and real-word evidence1,2 For personal use only CT PET PET/CT Fused 1 Anterior rib lesion Piflufolastat F-18 PSMA PET Scan • PSA 3.4 Patient on active surveillance No active treatment 2 Norib No riblesion
Slide 16: Innovation to meet the needs of patients and physicians
Innovation to meet the needs of patients and physicians Scaling innovation across entire patient journey by ‘painting the corners’ of the canvas For personal use only 1 High volume potential Access 18F loyalists 2 BiPASSTM – targets first line TLX593-Px (AlFluorTM) diagnostics. Platform enables flex
Slide 17: A multi-product prostate cancer therapy portfolio
A multi-product prostate cancer therapy portfolio Aligned to disease state, patient needs and clinical opportunity Hormone-sensitive Castration-resistant For personal use only Metastatic hormone-sensitive Metastatic castration-resistant Palliative TLX090-Tx TLX592-Tx Phase 3 TLX591-Tx in PSMA+ mCRPC
Slide 18: Therapeutic pipeline: late stage and next generation assets
Therapeutic pipeline: late stage and next generation assets Building a leadership position in urologic and neurologic oncology For personal use only PSMA: Prostate-specific membrane antigen. PDGFRα: Platelet-derived growth factor receptor alpha. CAIX: Carbonic anhydrase IX. mAb: Monoclonal antibody.
Slide 19: A catalyst rich 2026
A catalyst rich 2026 Select milestones for Therapeutics candidates Select milestones for Precision Medicine candidates Strategic collaboration with Regeneron Pixclara2 NDA resubmission (U.S.) accepted, For personal use only TLX591-Tx for mCRPC, ProstACT Global PDUFA goal date September 11, 2026 • Pa
Slide 20: Items of business
For personal use only Items of business
Slide 21: Financial and other formal reports
Item 1 - Financial and other formal reports To receive and consider the Financial report, Sustainability report, For personal use only Directors’ report and Auditor’s report for the financial year ended December 31, 2025. 21
Slide 22: Adopt the 2025 Remuneration report
Item 2 - Adopt the 2025 Remuneration report For personal use only To consider and, if thought fit, to pass the following resolution as a non-binding ordinary resolution: That the Remuneration report as set out in the Company's Annual Report (including Item 6.A "Directors and Senior Management" and 6
Slide 23: Voting: Adopt 2025 Remuneration report
Item 2 - Voting Adopt 2025 Remuneration report For personal use only Votes for Votes against Undirected Abstentions proxy votes* 92.59 4.45 2.97 92,212 votes % % % *All undirected proxy votes in favour of the Chairman of the Meeting will be voted in favour of the resolution 23
Slide 24: Re-election of Dr. Mark Nelson as Director
Item 3(a) - Re-election of Dr. Mark Nelson as Director For personal use only To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That Dr. Mark Nelson, being eligible, be re-elected as a Director of the Company. 24
Slide 25: Voting: Re-election of Dr. Mark Nelson
Item 3(a) - Voting Re-election of Dr. Mark Nelson as Director For personal use only Votes for Votes against Undirected Abstentions proxy votes* 81.01 2.89 16.10 45,386 votes % % % *All undirected proxy votes in favour of the Chairman of the Meeting and CEO will be voted in favour of the resolution.
Slide 26: Election of David Gill as Director
Item 3(b) - Election of David Gill as Director For personal use only To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That David Gill, being eligible, be elected as a Director of the Company. 26
Slide 27: Voting: Election of David Gill
Item 3(b) - Voting Election of David Gill as Director For personal use only Votes for Votes against Undirected Abstentions proxy votes* 83.81 0.09 16.10 35,829 votes % % % *All undirected proxy votes in favour of the Chairman of the Meeting and CEO will be voted in favour of the resolution. 27
Slide 28: Election of William Jellison as Director
Item 3(c) - Election of William Jellison as Director For personal use only To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That William Jellison, being eligible, be elected as a Director of the Company. 28
Slide 29: Voting: Election of William Jellison
Item 3(c) - Voting Election of William Jellison as Director For personal use only Votes for Votes against Undirected Abstentions proxy votes* 83.78 0.12 16.10 33,879 votes % % % *All undirected proxy votes in favour of the Chairman of the Meeting and CEO will be voted in favour of the resolution. 29
Slide 30: Election of Dr. Maria Rivas as Director
Item 3(d) - Election of Dr. Maria Rivas as Director For personal use only To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That Dr. Maria Rivas, being eligible, be elected as a Director of the Company. 30
Slide 31: Voting: Election of Dr. Maria Rivas
Item 3(d) - Voting Election of Dr. Maria Rivas as Director For personal use only Votes for Votes against Undirected Abstentions proxy votes* 83.79 0.11 16.10 44,268 votes % % % *All undirected proxy votes in favour of the Chairman of the Meeting and CEO will be voted in favour of the resolution. 31
Slide 32: Approve grant of deferred share rights to the MD & CEO
Item 4(a) - Approve the grant of deferred share rights to the MD & CEO For personal use only To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That approval be given for all purposes, including Listing Rule 10.14, for the grant of 27,121 deferred share righ
Slide 33: Voting: deferred share rights to MD & CEO
Item 4(a) - Voting Approve grant of deferred share rights to the MD & CEO For personal use only Votes for Votes against Undirected Abstentions proxy votes* 80.30 3.52 16.18 666,319 votes % % % *All undirected proxy votes in favour of the Chairman of the Meeting will be voted in favour of the resolut
Slide 34: Approve grant of performance share appreciation rights to MD & CEO
Item 4(b) - Approve the grant of performance share appreciation rights to the MD & CEO For personal use only To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That approval be given for all purposes, including Listing Rule 10.14, for the grant of 339,835 pe
Slide 35: Voting: performance share appreciation rights
Item 4(b) - Voting Approve grant of performance share appreciation rights to the MD & CEO For personal use only Votes for Votes against Undirected Abstentions proxy votes* 80.55 3.28 16.18 669,462 votes % % % *All undirected proxy votes in favour of the Chairman of the Meeting will be voted in favou
Slide 36: Approve the Equity Incentive Plan
Item 5 - Approve the Equity Incentive Plan and the issue of equity securities under the Equity Incentive Plan For personal use only To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That for the purposes of Listing Rule 7.2 (Exception 13(b)) and for all oth
Slide 37: Voting: Equity Incentive Plan
Item 5 - Voting Approve the Equity Incentive Plan and the issue of equity securities under the Equity Incentive Plan For personal use only Votes for Votes against Undirected Abstentions proxy votes* 68.96 12.27 18.77 105,084 votes % % % *All undirected proxy votes in favour of the Chairman of the Me
Slide 38: Approve potential termination benefits
Item 6 - Approve potential termination benefits For personal use only To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That approval be given for all purposes (including for sections 200B and 200E of the Australian Corporations Act 2001 (Cth) (the Corporat
Slide 39: Voting: potential termination benefits
Item 6 - Voting Approve potential termination benefits For personal use only Votes for Votes against Undirected Abstentions proxy votes* 98.87 1.04 0.10 763,767 votes % % % *All undirected proxy votes in favour of the Chairman of the Meeting will be voted in favour of the resolution. 39
Slide 40: Increase to maximum aggregate remuneration for Non-Executive Directors
Item 7 - Approve an increase to the maximum aggregate remuneration for Non-Executive Directors For personal use only To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That approval be given for all purposes, including Rule 8.3(a) of the – Company’s Constitu
Slide 41: Voting: Non-Executive Director remuneration increase
Item 7 - Voting Approve the increase to the maximum aggregate remuneration for Non-Executive Directors For personal use only Votes for Votes against Undirected Abstentions proxy votes* 67.41 13.82 18.77 117,508 votes % % % *All undirected proxy votes in favour of the Chairman of the Meeting will be
Slide 42: Issue of Share Appreciation Rights to Non-Executive Directors
Item 8 - Approve the issue of Share Appreciation Rights to Relevant Non-Executive Directors For personal use only To consider and, if thought fit, to pass the following resolutions as an ordinary resolution: That for the purposes of Listing Rule 10.14 and for all other purposes, the issue of share a
Slide 43: Voting: Share Appreciation Rights to Non-Executive Directors
Item 8 - Voting Approve the issue of Share Appreciation Rights to Relevant Non-Executive Directors Undirected For personal use only Votes for Votes against Abstentions proxy votes* a) Marie McDonald 47.35 % 36.46 % 16.19 % 725,733 votes (or nominee) b) David Gill 47.35 % 36.46 % 16.19 % 713,933 vote
Slide 44: Ratify the prior issue of Convertible Bonds
Item 9 - Ratify the prior issue of Convertible Bonds For personal use only To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That ratification be given for all purposes, including Listing Rule 7.4, for the prior issue of the Convertible Bonds, details of wh
Slide 45: Voting: Ratify prior issue of Convertible Bonds
Item 9 - Voting Ratify prior issue of Convertible Bonds For personal use only Votes for Votes against Undirected Abstentions proxy votes* 82.02 1.86 16.12 35,691 votes % % % *All undirected proxy votes in favour of the Chairman of the Meeting will be voted in favour of the resolution. 45
Slide 46: Final voting and close
For personal use only Final voting and close Thank you
Telix Pharmaceuticals — Shareholder Meeting (May 2026) on 6ix